A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds
…, P Kulanthaivel, MS Kuo, H Hemmerle…
Index: Sawayama, Andrew M.; Chen, Michael M. Y.; Kulanthaivel, Palaniappan; Kuo, Ming-Shang; Hemmerle, Horst; Arnold, Frances H. Chemistry - A European Journal, 2009 , vol. 15, # 43 p. 11723 - 11729
Full Text: HTML
Citation Number: 90
Abstract
Abstract Herein we demonstrate that a small panel of variants of cytochrome P450 BM3 from Bacillus megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 mammalian metabolites for two marketed drugs, verapamil and astemizole, and one research compound. The most active enzymes support preparation of individual metabolites for preclinical bioactivity and toxicology evaluations. Underscoring their potential utility in ...
Related Articles:
[Wang, Cheng; Wang, Tao; Zhou, Nan; Pan, Xiao-Yan; He, Huai-Zhen Journal of Asian Natural Products Research, 2014 , vol. 16, # 3 p. 304 - 311]
Antagonistes calciques. I. Remplacement du groupe diméthoxy-3, 4 phényléthyle du vérapamil
[Laguerre, M.; Boyer, C.; Carpy, A.; Panconi, E.; Cognic, F.; Vaugien, B. European Journal of Medicinal Chemistry, 1990 , vol. 25, # 4 p. 351 - 359]
Antagonistes calciques. I. Remplacement du groupe diméthoxy-3, 4 phényléthyle du vérapamil
[European Journal of Medicinal Chemistry, , vol. 25, # 4 p. 351 - 359]
Antagonistes calciques. I. Remplacement du groupe diméthoxy-3, 4 phényléthyle du vérapamil
[European Journal of Medicinal Chemistry, , vol. 25, # 4 p. 351 - 359]
[Rapid Communications in Mass Spectrometry, , vol. 24, # 7 p. 939 - 957]